



BSE Limited,
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: 530019

July 29, 2025
National Stock Exchange of India Limited,
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai - 400051

Symbol: JUBLPHARMA

Sub.: Outcome of the Board Meeting held on July 29, 2025

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sirs,

Pursuant to the provisions of Regulation 30 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on Tuesday, July 29, 2025 at 10:45 A.M. and concluded at 01:15 P.M., has, inter alia, approved the following:

- (i) Re-appointment of Deloitte Touche Tohmatsu India LLP, as Internal Auditors of the Company, for a period of 3 consecutive years i.e. FY 2025-26 to FY 2027-28.
- (ii) Grant of 1,21,560 Stock Options/ Restricted Stock Units (RSUs) to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.

Details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided in Annexure A and B.

The above mentioned documents will be simultaneously posted on the Company's website at www.jubilantpharmova.com.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary
Encl: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular dated November 11, 2024:

Annexure – A

Name	Deloitte Touche Tohmatsu India LLP
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-Appointment
Date of appointment/re- appointment/cessation (as applicable) & term of appointment/ re-appointment;	Re-appointment in the Board Meeting held on July 29, 2025, for a term of 3 consecutive years from FY 2025-26 to FY 2027-28.
Brief Profile (in case of appointment)	<p>Deloitte India has more than 36,000 professionals operating out of 14 cities - Ahmedabad, Bengaluru, Bhubaneswar, Chennai, Coimbatore, Goa, New Delhi, Hyderabad, Jamshedpur, Kochi, Kolkata, Mumbai, Noida and Pune.</p> <p>They are committed to becoming the undisputed leader in professional services in the areas of Assurance, Tax, Strategy, Risk & Transactions, Technology & Transformation. They serve public and private clients spanning multiple industries.</p> <p>Deloitte draw their strength from their people, which include 2506+ professionals in Assurance, 2835+ in Strategy, Risk & Transactions, 3216+ in Tax, 12,244+ in Technology & Transformation. Deloitte take pride in their ability to serve their clients distinctively by solving complex challenges, inspire their talent to deliver outstanding values and support their communities and society we live in. Their multi-disciplinary model ensures they serve their clients across businesses and deliver the right combination of local insight and international expertise.</p>
Disclosure of relationship between directors (in case of appointment of a director)	Not Applicable

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure – B

S. No.	Particulars	Details
1	Brief details of Stock options granted	Grant of 1,21,560 Stock Options/ RSUs to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee and Board of Directors
2	Whether the scheme is in terms of SEBI (Share Based Employee Benefits) Regulations, 2021	Yes
3	Total number of shares covered by these stock options	1,21,560 Equity Shares of face value Re.1 each
4	Pricing Formula (Exercise Price)	The Exercise Price is Re. 1 each i.e. face value per equity share of the Company.
5	Options Vested (Vesting Schedule)	<p>Subject to fulfilment of pre-vesting conditions, RSU's/Stock Options will vest as under:</p> <p>Vesting Criteria of 1,03,813 RSU's of Re. 1: At the end of Financial Year 2028 based on performance criteria as laid down in grant letter</p> <p>Vesting Criteria of 13,447 Stock Units: At the end of 3rd Year</p> <p>Vesting Criteria of 4,300 Stock Units: At the end of 1st Year</p>
6	Time within which option may be exercised (Exercise Period)	1,21,560 Stock Options shall be exercisable within a maximum period of 1 (one) year from the date of vesting of Options subject to the terms of Jubilant Pharmova Employees Stock Option Plan 2018.
7	Brief details of significant terms	Vesting of Options is subject to a minimum vesting period of 1 (one) year and maximum

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



		vesting period of 5 (five) years from the date of grant as per Jubilant Pharmova Employees Stock Option Plan 2018
--	--	---

Note: The requirements prescribed under sub-clauses (g) to (k), (m) & (n) of Clause 10 of Para B of Annexure 18 of SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are not applicable.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624